MEPSGEN

MEPSGEN is a biotechnology company that develops human microphysiological systems (MPS), also known as organ-on-a-chip, to predict drug toxicity and efficacy more accurately. Their platform, MEPS-X, enables researchers to model human physiology and pathology at tissue levels, providing alternatives to animal testing. In addition to its MPS platforms, MEPSGEN specializes in scalable nanoparticle production technology, including its NanoCalibur system, which supports lab-scale to GMP manufacturing of lipid nanoparticles (LNPs) for mRNA, gene therapy, and targeted drug delivery. The company also maintains a pipeline of nanomedicine candidates targeting Alzheimer's disease and brain tumors.